Retina Mythbusters: Dispelling Common Myths About the Use of Dual Inhibition Therapy Versus Anti-VEGF in Retinal Vascular Diseases

Retina Mythbusters: Dispelling Common Myths About the Use of Dual Inhibition Therapy Versus Anti-VEGF in Retinal Vascular Diseases is organized by Paradigm Medical Communications, LLC.

Release Date: March 25, 2024
Expiration Date: March 25, 2025

Description:
Uncertain about the role of novel therapies in retinal vascular diseases? Who you gonna call? Mythbusters! Join our expert faculty as they dispel common myths and misconceptions about dual inhibition therapy and high-dose anti-vascular endothelial growth factor (VEGF) therapy, including those surrounding their durability, effects on disease activity, patient selection, retreatment criteria, and more.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Differentiate dual inhibition therapy from anti-VEGF therapy based on key anatomic outcomes that demonstrate direct effects on the pathophysiology of retinal vascular diseases
• Describe the significance of retreatment criteria used in recent clinical trials of dual inhibition therapy and high-dose anti-VEGF therapy
• Personalize treatment decisions for patients with retinal vascular diseases that demonstrate application of the latest evidence to inform appropriate selection and dosing of therapy